Business Context and Reporting Period
This Form 8-K is a Current Report filed by Ocuphire Pharma, Inc. (not Opus Genetics, Inc.) on May 10, 2024. The filing serves as a Regulation FD disclosure to announce that the Company plans to share a presentation (Exhibit 99.1) in upcoming meetings with investors. The registrant is incorporated in Delaware and trades on the Nasdaq Stock Market under the symbol OCUP.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding investor communications and does not contain financial statements or performance data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The only reported event is the intention to distribute a presentation to investors.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in Item 7.01 and the attached presentation (Exhibit 99.1) is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information shall not be deemed incorporated by reference in any other filing unless expressly stated. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Verify the correct registrant name is Ocuphire Pharma, Inc. (OCUP), not Opus Genetics, Inc.
- Review the attached Exhibit 99.1 (Presentation) for actual business updates, as the 8-K text only announces its existence.
- Confirm that the presentation content is not automatically incorporated by reference into other SEC filings.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial metrics absent from this report.